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Background: Gefitinib, an epidermal growth factor receptor ty-
rosine kinase inhibitor, has demonstrated a response rate of 9%–18%
in relapsed non-small cell lung cancer (NSCLC) patients. The
probability of response to gefitinib was not influenced by response to
previous chemotherapy. Preclinical studies have suggested that cele-
coxib, a cyclooxygenase-2 inhibitor, has antitumor activity in
NSCLC and can enhance the activity of EGFR inhibitors. We
conducted a phase II study evaluating the combination of gefitinib
and celecoxib in platinum-refractory NSCLC patients, defined as
patients whose disease had progressed on platinum-based chemo-
therapy or within 3 months of completing such therapy.
Methods: Platinum-refractory NSCLC patients with performance
status of 0–2 and adequate organ function were included. Patients
should not have been on a NSAID for 30 continuous days before
study enrollment. Patients were treated with gefitinib 250 mg daily
and celecoxib 400 mg twice daily. Disease assessment was per-
formed every 8 weeks.
Results: Twenty-seven patients were enrolled. The response rate
was 7% (2/27). The median time to progression was 2.2 months, and
the median survival was 4.6 months. One female, nonsmoking
patient is progression free more than 3 years after study enrollment.
The drug combination was well tolerated, with the most common
adverse effects being skin rash and diarrhea.
Conclusion: In unselected platinum-refractory NSCLC patients, the
response rate to the combination of celecoxib and gefitinib was
similar to that observed with gefitinib alone.
Key Words: Epidermal growth factor receptor, Cyclooxygenase-2,
Gefitinib, Celecoxib, Non-small cell lung cancer.
(J Thorac Oncol. 2007;2: 299–305)
Lung cancer remains the most common cause of cancer-related mortality in the United States.1 The high rate of
mortality is because most patients have advanced-stage dis-
ease at presentation. Platinum-based doublet chemotherapy
does improve overall survival and quality of life in advanced
non-small cell lung cancer (NSCLC) patients. However, the
benefits of such therapy, with median time to progression of
4 months and median survival of 8 months, are modest.2 Two
chemotherapy drugs, docetaxel and pemetrexed, and erlo-
tinib, are currently approved for the management of relapsed
NSCLC patients. The response rate with these agents is
approximately 9% and the median survival is 7–8 months.3,4
Tumor progression within 3 months of completing first-line
therapy, designated as chemorefractoriness, is a poor prog-
nostic factor in relapsed NSCLC patients. The response rate
in these patients, with either docetaxel or pemetrexed, is less
than 5%.3
Epidermal growth factor receptor (EGFR), a receptor
tyrosine kinase, is expressed in many NSCLCs and is in-
volved in many aspects of carcinogenesis.5 Based on EGFR
expression in NSCLC and promising preclinical data, ge-
fitinib was evaluated for the management of relapsed NSCLC
patients. In two large phase II studies, gefitinib improved
disease-related symptoms in 40% of the patients and demon-
strated a response rate of 9% to 18%.6,7 Time from initial
diagnosis, a surrogate for chemorefractoriness, did not influ-
ence the possibility of response to gefitinib. Based on the
results of these studies, gefitinib was approved for the man-
agement of relapsed NSCLC patients.
Cyclooxygenase (COX) is a rate-limiting enzyme in-
volved in the conversion of arachidonic acid to prostaglan-
dins (PGs). There are two isoforms of COX: COX-1, a
constitutive enzyme expressed in most cells, and COX-2, an
inducible isoform of COX.8 COX-2 is overexpressed in
neoplastic tissues in response to various stimuli9–11 and
through the production of PGs, COX-2 is involved in various
processes of cancer formation and progression.12–15 Many
NSCLC tumors express COX-2, and preclinical evidence
suggests that the selective COX-2 inhibitor celecoxib can
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inhibit NSCLC tumor growth, alone and in conjunction with
chemotherapy drugs.16–18 In a randomized study conducted in
patients with familial adenomatous polyposis (FAP), cele-
coxib 400 mg twice daily demonstrated a statistically signif-
icant reduction in the number of colonic polyps, providing the
first clinical evidence that COX-2 inhibitors can influence
precancerous conditions.19 A lower dose of 100 mg twice
daily failed to demonstrate a statistically significant decline in
the number of colonic polyps.
Preclinical data suggest that there is overlap between
the EGFR and COX-2 pathways.20 In colon cancer tumor
models, EGFR signaling induces COX-2 expression and
increased PG production, whereas COX-2–derived PGE2 can
enhance signaling through EGFR.21–23 In addition, recent
studies have shown that COX-2, through the production of
PGE2 may sensitize tumor cells to EGFR-TKIs.24,25 Preclin-
ical studies have also shown that the combination of EGFR
inhibitors and COX-2 inhibitors is more effective in inhibit-
ing tumor formation than either agent alone.26,27
Based on the activity of gefitinib in NSCLC patients,
the preclinical activity of celecoxib in NSCLC cell lines and
the possibility of overlap between the EGFR and COX-2
pathways, we conducted a phase II study evaluating the
benefits of adding celecoxib to gefitinib in relapsed NSCLC
patients. Celecoxib was administered at a dose of 400 mg
twice daily based on the results of the study by Steinbach et
al.19 in FAP patients. We restricted the eligibility to NSCLC
patients who had progressed on first-line platinum-based
doublet chemotherapy or within 3 months of completing such
therapy.
MATERIALS AND METHODS
Study Design
The primary objective of this study was to assess the
response rate with the combination of gefitinib and celecoxib
in NSCLC patients designated as platinum refractory, based
on progression of disease on or within 3 months of complet-
ing a platinum-based doublet regimen. The secondary end
points were overall survival (OS), time to progression (TTP),
and toxicity. TTP was defined as the time from the first day
of treatment until the date when progressive disease was
documented or death from any cause, whichever came first.
Surviving patients who did not progress were censored for
TTP as of the date of their last tumor assessment. OS was
defined as the time from the first day of treatment until the
date of death from any cause. Surviving patients were cen-
sored for OS as of the date they were last known to be alive.
Patient Selection
Patients aged 18 years and older with histologically or
cytologically confirmed platinum-refractory NSCLC were
eligible for the study. Patients had to be of performance status
(PS) 0–2 and could have received other treatments after the
platinum-based therapy. Patients were required to have at
least one measurable lesion, adequate hepatic (bilirubin at the
upper limit of normal [ULN] or less, aspartate aminotrans-
ferase and alanine aminotransferase 2.5 times the ULN,
alkaline phosphatase five times the ULN or less), renal
(creatinine 1.5 times the ULN), and hematologic function
(hemoglobin 8 g/dL, neutrophil count 1.5  109/liter,
platelets100,000 109/liter). Female patients of reproduc-
tive age were required to have a negative pregnancy test, and
all patients were advised to use adequate contraception while
on therapy.
Patients were required to be at least 2 weeks from
previous chemotherapy and 4 weeks after an investigational
agent before study enrollment and should have recovered
from any adverse effects of previous therapy. Patients were
excluded if they were on nonsteroidal anti-inflammatory
drugs (NSAIDs) for more than 30 continuous days before
enrollment. Patients could not take any other NSAIDs while
on study except aspirin at a dose of 325 mg/day. Patients
were excluded if they had allergy to sulfa drugs or a history
of gastrointestinal hemorrhage or myocardial infarction, or
cerebrovascular event within 6 months. Patients with a his-
tory of a venous thromboembolic phenomenon within 4
weeks of study entry were excluded. Patients with brain
metastases were allowed as long as the brain metastases had
been treated, and the patient had no symptoms from the brain
metastases. Any patient with body weight of 50 kg was
excluded because gefitinib had not been studied in such
patients. Patients with any condition that precluded taking the
study drugs were not eligible.
Response rates were assessed every 8 weeks according
to the Response Evaluation Criteria in Solid Tumors.28 Tox-
icity was graded according to the National Cancer Institutte
Common Toxicity Criteria, version 2.0.
All patients were required to provide a signed, in-
formed consent before enrollment. The Human Investigation
Committee of Wayne State University approved the protocol.
Treatment
Gefitinib was provided by AstraZeneca. Patients were
instructed to take gefitinib 250 mg once daily and celecoxib
400 mg twice daily with meals. Each 4-week period was
considered a cycle. While on therapy, each patient was
assessed every 2 weeks with history and physical examina-
tion and laboratory evaluation. After four cycles, if the patient
did not have any toxicity higher than grade 2, patients could
be evaluated every 4 weeks. Disease assessment was done
after every two cycles. Standard measures were to be used to
manage skin rash and diarrhea related to gefitinib. The dose
of celecoxib was reduced by 25% for increase in serum
creatinine of 50%–100% over baseline, and celecoxib was to
be held for increase in creatinine 100% over baseline. Both
drugs were to be held for a maximum of 14 days for any
grade 3–4 toxicity not accounted for by disease progression.
Patients could restart both drugs at the same dose if the
patient recovered to grade 1 toxicity.
Statistical Methods
This phase II trial was planned with a Simon two-stage
design.29 The particular design chosen has Simon-like prop-
erties, and results from the Simon algorithm modifications of
Green and Dahlberg.30 The primary end point was complete
or partial response (CRPR). We wished to distinguish these
regions of the true, unknown response rate: at most 0.05
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versus at least 0.20. The two-stage design called for a max-
imum of 27 response assessable (R-E) patients, 18 in stage 1
and nine in stage 2. Patients were considered R-E if they
completed at least 2 weeks of therapy. The design had power
of 0.80, overall type I error of 0.05, and (via the Green and
Dahlberg method30) a type II (i.e., false negative) error rate of
0.02 for stage 1 of the two-stage design. At least one response
among the first 18 R-E patients was needed to justify begin-
ning stage 2 of accrual. In the study results, the response rate
is reported based on all 27 registered patients, according to
the intent-to-treat principle.
Exact minimum-width 90% confidence intervals (CIs)
for response and toxicity rates were calculated using the
Casella method31 as implemented in StatXact software.32
Standard Kaplan-Meier estimates of the censored TTP and
OS distributions were computed. Due to the small sample
sizes, survival statistics (e.g., median, 1-year rate) were
estimated more conservatively using linear interpolation33
among successive event times on the Kaplan-Meier curves.
RESULTS
Patient Characteristics
Twenty-seven patients were enrolled from May of 2003
to September of 2004 (Table 1). The median age was 59 years
(range, 35–74 years). The majority of the patients were males
(63%) and white (70%). All patients but one had stage IV
NSCLC at study entry, and 26% of the patients had a PS of
2. One patient with breast cancer 7 years before diagnosis
developed a sternal mass, lung lesions, and supraclavicular
adenopathy. This patient was diagnosed as NSCLC and was
treated with platinum-based doublet chemotherapy. The pa-
tient was enrolled in this trial at progression. The patient had
stable disease on therapy for 5 months with subsequent mild
progression. Due to an unusually prolonged clinical course
despite lack of response to any therapy, a review of the
pathology from the breast primary (obtained from an outside
institution) and the most recent biopsy was conducted, and it
suggested similarity. This patient is still alive without any
therapy other than zoledronic acid. This patient has been
included in all end points for an intent-to-treat analysis.
Response and Survival
Among the 27 patients enrolled, two patients (7%, 90%
CI: 0.02–0.20) had a PR to the combination of gefitinib and
celecoxib. Six other patients had stable disease, for an overall
clinical benefit rate of 30% (PR  stable disease, 90% CI:
0.16–0.45). Of the two patients who had a response, one
patient continues to be on gefitinib for 36 months. This
female nonsmoking patient, who had adenocarcinoma, took
the combination for 20 months. However, after the data
regarding cardiovascular risks with the use of celecoxib were
released, the patient decided to discontinue celecoxib and
continue only on gefitinib. This patient continues to have a
PR with some mild changes in the pleura persisting. The
other patient who had a response was a male who was a
former smoker (10 pack-years) with poorly differentiated
carcinoma.
The response rate among nonsmokers was 25% (1/4),
although one patient never started on therapy and died within
11 days of study registration from progressive disease. Only
one of eight current smokers had stable disease, which lasted
for 3 months.
The median time to progression was 2.2 months, and
median survival was 4.6 months (Table 2). The 1-year sur-
vival rate was 16%, and at 1 year, 8% of the patients had not
progressed (Figures 1 and 2).
TABLE 1. Patient Demographics
No. 27
Age, y
Range 35–74
Median 59
Gender N (%)
Males 17 (63)
Females 10 (37)
Race, no. (%)
White 19 (70)
Black 6 (22)
Asian 2 (8)
PS (ECOG)
0,1 20 (74)
2 7 (26)
Smoking history no. (%)
Current 10 (37)
Former 13 (48)
Nonsmokers 4 (15)
Previous chemotherapy regimens
1 16 (59)
2 11 (41)
Stage
IV 26 (96)
IIIB 1 (4)
Histology*
Adenocarcinoma 11 (42)
Squamous cell 4 (15)
NOS 8 (31)
Large cell 3 (12)
*One patient had breast cancer and was wrongly enrolled on the study.
PS, performance status; ECOG, Eastern Cooperative Oncology Group; NOS, not
otherwise specified.
TABLE 2. Time to Event End Points
Event Statistics No. Events
Point
Estimate
90% Confidence
Interval
Response rate 27 2 7% 2%–20%
Time to progression 27 26
Median 2.2 mo 1.7 mo–2.9 mo
12-mo rate 8% 0%–17%
Overall survival 27 25
Median 4.6 mo 2.7 mo–6.2 mo
12-mo rate 16% 4%–27%
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Toxicity (Table 3)
The combination was well tolerated and the adverse
effects attributable to the drugs were very few. Cutaneous
adverse effects were observed in seven patients, but none of
these were more than grade 2. Diarrhea was observed in five
patients, with only one patient developing grade 3 toxicity.
Five patients were admitted with respiratory failure and
clinical suspicion of pneumonitis. However, all patients had
evidence of disease progression. One patient did have
radiographic findings suggestive of pneumonitis but also
had evidence of disease progression. None of the patients
developed a cardiovascular event or episodes of venous
thromboembolism. COX-2 inhibitors appear to increase
the risk of vascular episodes.34 It is quite possible that we
FIGURE 1. The Kaplan-Meier esti-
mate of time to progression in the
27 patients with platinum-refrac-
tory non-small cell lung cancer
who were treated with gefitinib
and celecoxib. The dashed lines
represent the 90% confidence lim-
its about each successive estimate
of the progression-free rate.
FIGURE 2. The Kaplan-Meier esti-
mate of overall survival in the 27
patients with platinum-refractory
non-small cell lung cancer enrolled
in the study. The dashed lines rep-
resent the 90% confidence limits
about each successive estimate of
the survival rate.
TABLE 3. Toxicity
Toxicity Type Cutaneous Diarrhea Edema Renal Fatigue Pulmonary
Grade 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
No. of patients 4 3 3 1 1 1 2 2 1 3 1 1*
*Five patients were admitted to the hospital with clinical suspicion of pneumonitis. However, only one patient
was deemed to have pneumonitis.
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did not observe these episodes due to the short duration of
therapy with COX-2 inhibitors in most patients in this
study. Renal dysfunction was observed in three patients.
This was characterized by increase in serum creatinine. In
each of these patients, the dose of celecoxib was reduced.
The creatinine improved in two patients and in one patient
did not change.
DISCUSSION
In this trial, the response rate and survival with the
combination of gefitinib and celecoxib were similar to those
observed with single-agent gefitinib. We limited the study
population to patients whose disease had progressed on plat-
inum-based therapy or within 3 months of completion of such
therapy and designated them as platinum-refractory patients.
Our objective in restricting the eligibility to these patients
was to limit the heterogeneity of patients commonly observed
in phase II trials of relapsed NSCLC patients. In addition, the
activity of approved chemotherapy drugs in platinum-refrac-
tory patients appears to be limited, whereas data from phase
II studies of gefitinib suggest that response to the previous
chemotherapy regimen did not influence the probability of
benefit.
Gefitinib was originally approved based on a response
rate of 9% in a large phase II study.7 However, based on a
lack of significant benefit in a randomized phase III study,
gefitinib was withdrawn from the U.S. market.35 In subset
analysis of the randomized study, survival advantage with
gefitinib was observed in nonsmokers and in patients of Asian
ethnicity. The withdrawal was also prompted by results
observed with erlotinib, another EGFR-TKI, which did dem-
onstrate significant survival improvement in relapsed NSCLC
patients.4 There has been intense speculation regarding the
disparity in results with gefitinib and erlotinib. It appears that
one of the possible reasons for the disparity may be differ-
ences in drug levels achieved at standard doses with the two
drugs.36,37
The results of initial phase II studies of EGFR-TKIs
suggested that patients with clinical characteristics of non-
smoking status, female gender, Asian ethnicity, and adeno-
carcinoma histology had a higher likelihood of clinical ben-
efit.38,39 Retrospective evaluation of tumors of patients with a
response identified that the presence of somatic activating
mutations in the tyrosine kinase domain of the EGFR gene is
predictive of response to EGFR-TKIs.40,41 It appears that
EGFR mutations lead to tumor dependency on the EGFR
pathway for survival and blocking of this pathway by ge-
fitinib or erlotinib leads to apoptosis.42 Subsequently, other
investigators have suggested that increased EGFR gene copy
number and EGFR expression are more predictive of benefit
from EGFR-TKIs.43 The importance of each of these factors
in predicting benefit from EGFR-TKIs remains to be deter-
mined in prospective clinical trials. Interestingly, EGFR mu-
tations and increased EGFR gene copy number occur more
frequently in tumors of NSCLC patients with clinical char-
acteristics that are predictors of increased likelihood of ben-
efit from EGFR-TKIs, particularly nonsmoking status.42,43
Based on preclinical data regarding the role of COX-2
in carcinogenesis, COX-2 inhibitors have been evaluated in
cancer prevention and therapy. In prospective, randomized
trials, celecoxib reduced the number of colonic polyps in pa-
tients with FAP and more recently showed a reduction in the
number of colon cancers and precancerous lesions in individu-
als with a history of colonic polyps.18,44,45 However, COX-2
inhibitors have not consistently demonstrated benefits in
therapeutic trials.46–48 In a recently reported randomized
study conducted by Cancer and Leukemia Group B, addition
of celecoxib to platinum-based doublet chemotherapy did not
provide any additional benefit in advanced NSCLC patients.49
This lack of benefit from COX-2 inhibitors in established
tumors may be related to greater redundancy of carcinogenic
pathways in advanced cancers than in precancerous lesions.
A retrospective analysis of the Cancer and Leukemia Group
B study suggests that patients with tumors that expressed
COX-2 had improved survival with the addition of celecoxib
to chemotherapy.
Csiki et al.46 evaluated docetaxel in combination with
celecoxib in patients with previously treated NSCLC. Al-
though the overall results did not suggest an improvement in
survival with the addition of celecoxib, the investigators did
observe that patients who had the greatest proportional drop
in urinary PGE-M levels, a metabolite of PGE2 and a marker
of systemic PGE2 levels, had a substantially reduced risk of
death compared with patients in whom no change in PGE-M
levels were observed. Thus, it is possible that celecoxib is
beneficial only in NSCLC patients in whom the urinary
PGE-M levels decline and therefore the benefits of adding
celecoxib to an EGFR-TKI may also be restricted to these
patients. Lilenbaum et al.50 also did not observe any benefit
from the addition of celecoxib to chemotherapy doublets in
relapsed NSCLC patients. In an editorial accompanying the
Lilenbaum et al. study, Ciski and Johnson51 suggest that
appropriate characterization of the enzymes involved in
PGE2 synthesis and metabolism in patient’s tumor may be
important in selecting patients for treatment with COX-2
inhibitors. They suggest that in certain NSCLC, 15-PG de-
hydrogenase, an enzyme responsible for PGE2 elimination,
may be down-regulated, and in patients with these tumors,
celecoxib may actually promote tumor proliferation and
therefore may be detrimental. Thus, preselection of NSCLC
patients based on tumor expression of COX-2 and the en-
zymes involved in PG metabolism may be important to
observe an antitumor effect of celecoxib. Lack of such pre-
selection may be a reason for the lack of benefit with the
addition of celecoxib to gefitinib in our trial.
Two other recently reported studies suggest that in
unselected patients with advanced NSCLC, the addition of a
COX-2 inhibitor to an EGFR-TKI does not improve efficacy.
Fidler et al.52 reported a response rate of 8% (2/26) in
relapsed NSCLC patients with the combination of erlotinib
and celecoxib. Agarwala et al.53 reported the results of a
study evaluating the combination of gefitinib and celecoxib as
frontline therapy and found a response rate of 16% (5/31).
These results contrast with the promising response rate of
33% (7/21) observed by Reckamp et al.54 in a phase I study
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seeking an optimal biological dose of celecoxib in combina-
tion with a standard dose of erlotinib. In this study, the
investigators defined the optimal biological dose of cele-
coxib, based on reduction in urinary PGE-M levels, to be 600
mg twice daily. It is possible that the superior response rates
in this study may be related to the higher dose of celecoxib.
However, responses in the study by Reckamp et al. were also
observed in patients who received a celecoxib dose lower
than 600 mg twice daily. These investigators are planning
to conduct a phase II trial evaluating the benefits of adding
celecoxib at this dose to erlotinib in advanced NSCLC
patients.
The first patient enrolled in this trial is progression free
for more than 3 years. This patient is a nonsmoking female
with adenocarcinoma, clinical features that predict for higher
likelihood of benefit from EGFR-TKIs. We did not have an
adequate tumor sample to assess EGFR mutation status or
EGFR gene copy number. The impressive clinical outcome of
this patient led us to speculate that the combination of
EGFR-TKI and COX-2 inhibitor may be most effective in
NSCLC with EGFR mutations. We therefore conducted in
vitro studies to test this hypothesis. Celecoxib enhanced
efficacy of both EGFR-TKIs in two EGFR-mutated cell lines
but did not do so in a cell line with wild-type EGFR.55 It is
likely that due to dependency on the EGFR pathway in
mutated tumors, the overlap between the EGFR and COX-2
pathways may be more relevant in these tumors and therefore
the combination of EGFR-TKI and celecoxib may be most
active in these tumors. It is also important to note that urinary
PGE-M level, a marker of systemic PGE2 levels, is elevated
in smokers than in nonsmokers and that celecoxib reduces the
PGE-M levels to a greater extent in former and never smok-
ers. It is therefore possible that celecoxib may have greater
antitumor effect on never smokers than on former/current
smokers,46,56 and therefore the addition of celecoxib to
EGFR-TKI may be more beneficial in NSCLC patients who
have never smoked.
In conclusion, the results of this study show that the
addition of celecoxib to gefitinib is not beneficial in uns-
elected platinum-refractory NSCLC patients. Recent studies
and observations suggest that EGFR-TKIs and COX-2 inhib-
itors are likely to be beneficial in NSCLC patients with
specific molecular characteristics in their tumors. Based on
these data, future studies should evaluate the combination of
EGFR-TKI and celecoxib in NSCLC patients with tumors
that have molecular characteristics such as EGFR mutations
and/or COX-2 expression and also evaluate the combination
with celecoxib dosed at 600 mg twice daily to obtain the most
optimal COX-2 inhibition.
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